CURIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.9 USD | -7.38% |
|
-13.32% | -45.88% |
| 14/05 | Transcript : Curis, Inc. - Special Call | |
| 14/05 | Curis, Inc. Announces Additional Data from Take Aim Leukemia Study | CI |
| Sales 2024 * | 87.83L 73Cr | Sales 2025 * | 87.95L 73Cr | Capitalization | 4.07Cr 338.92Cr |
|---|---|---|---|---|---|
| Net income 2024 * | -4.8Cr -400.01Cr | Net income 2025 * | -5.3Cr -441.68Cr | EV / Sales 2024 * | 4.63 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.62 x |
| P/E ratio 2024 * |
-1.12
x | P/E ratio 2025 * |
-1.5
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Curis, Inc.
More recommendations
More press releases
| 1 day | -7.38% | ||
| 1 week | -13.32% | ||
| Current month | -33.40% | ||
| 1 month | -34.91% | ||
| 3 months | -36.52% | ||
| 6 months | -45.88% | ||
| Current year | -45.88% |
1 week
6.63
8.42
1 month
6.3210.91
Current year
6.3217.49
1 year
3.8018.00
3 years
3.80180.80
5 years
3.80348.00
10 years
3.80375.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 29/16/29 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 26/22/26 |
| Chief Tech/Sci/R&D Officer | - | 03/22/03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kenneth Kaitin
BRD | Director/Board Member | 71 | 01/03/01 |
Martyn Greenacre
CHM | Chairman | 82 | 14/00/14 |
James Dentzer
CEO | Chief Executive Officer | 57 | 29/16/29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/24/28 | 6.9 | -7.38% | 84,425 |
| 27/24/27 | 7.45 | -0.67% | 26,371 |
| 26/24/26 | 7.5 | -4.34% | 15,935 |
| 25/24/25 | 7.84 | -4.39% | 17,532 |
| 24/24/24 | 8.2 | +3.02% | 36,319 |
Delayed Quote Nasdaq, June 29, 2024 at 01:30 am IST
More quotes
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Calendar
01/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.9
USD
Average target price
78
USD
Spread / Average Target
+1,030.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.88% | 4.07Cr | |
| +19.41% | 4.55TCr | |
| -8.62% | 3.85TCr | |
| +38.65% | 3.81TCr | |
| +26.95% | 3.07TCr | |
| -13.50% | 2.6TCr | |
| +10.74% | 2.59TCr | |
| +44.87% | 1.41TCr | |
| +34.36% | 1.27TCr | |
| -7.14% | 1.13TCr |
- Stock Market
- Equities
- CRIS Stock
